Booster vaccination of healthy adults with VZV antibody but without a VZV-specific cell-mediated immune response

Berger, R.; Amstutz, I.; Just, M; Just, Vroni; Luescher, D

doi:10.1016/s0166-3542(85)80037-1

Cited by 12 publications

(3 citation statements)

References 2 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The first trial of Berger et al in 33 subjects showed that 17 vaccinees developed a strong VZV-specific LPA response, and 11 developed a weak response [5]. The second Berger trial chose subjects on the basis of a negative VZV skin test, a procedure that is probably immunizing in its own right and would complicate evaluation of the vaccine [3].…”

Section: Clinical Trials With Candidate Hz Vaccinesmentioning

confidence: 99%

Use of varicella vaccines to prevent herpes zoster in older individuals

Levin

2001

Immunity to and Prevention of Herpes Zoster

View full text Add to dashboard Cite

Summary. It is likely that the frequency and severity of herpes zoster in older people is the result of an age-related decline in varicella-zoster virus-specific T-cell mediated immunity. Numerous trials of vaccines to boost these responses have demonstrated their safety and immunogenicity. Both live attenuated and inactivated vaccines have been studied. Persistence of booster responses is doserelated, and the half-life of some boosted measures of T-cell mediated immunity exceeds 5 years. Although these trials have been hampered by uncertainty about the critical immune responses to evaluate, the stage is set for a double-blind, placebo-controlled trial of sufficient size to determine efficacy. Such a trial is now underway.

show abstract

Section: Clinical Trials With Candidate Hz Vaccinesmentioning

confidence: 99%

Use of varicella vaccines to prevent herpes zoster in older individuals

Levin

2001

Immunity to and Prevention of Herpes Zoster

View full text Add to dashboard Cite

show abstract

“…11 Varicella-zoster virus-specific, cell-mediated immunity is enhanced by vaccination with live, attenuated VZV vaccination. 12 In addition, researchers have demonstrated that VZV vaccination enhances both humoral and cellular VZV-specific immune responses. 13 Following vaccination with zoster vaccine live, VZV antibody levels are increased.…”

Section: Pharmacologymentioning

confidence: 99%

Zoster Vaccine Live

Kockler

McCarthy

2007

Pharmacotherapy

View full text Add to dashboard Cite

Herpes zoster is a neurocutaneous disease caused by the varicella-zoster virus and is associated with significant morbidity and long-term sequelae in older adults. Until recently, treatment options for these complications have been primarily targeted at disease state management and symptom relief. Zoster vaccine live is the first vaccine approved for the prevention of herpes zoster. The vaccine was approved by the United States Food and Drug Administration for adults aged 60 years or older. Results of the Shingles Prevention Study demonstrated that in older individuals, administration of zoster vaccine live reduces the burden of illness associated with herpes zoster by 61.1%, the frequency of herpes zoster pain and discomfort by 51.3%, and the frequency of postherpetic neuralgia by 66.5%. Overall, adverse events reported in clinical trials of zoster vaccine live were classified as mild. Events that occurred more frequently in zoster vaccine live recipients than in placebo recipients included injection site reactions, headache, respiratory infections, fever, flu syndrome, diarrhea, rhinitis, skin disorders, respiratory disorders, and asthenia. The Centers for Disease Control and Prevention's Advisory Committee on Immunization Practices recently recommended universal vaccination for those 60 years of age and older, including those who have experienced previous episodes of shingles.

show abstract

“…21 Pilot studies indicated that VZV CMI could be boosted in subjects 60 to >90 years of age by administration of investigational live attenuated Oka/Merck VZV vaccines. 15,21,22,[27][28][29][30][31] Following preliminary trials to assess the safety and immunogenicity of an investigational high potency live attenuated Oka/Merck VZV vaccine ("zoster vaccine") in elderly subjects, including persons with diabetes or chronic obstructive lung disease, and to establish optimal vaccine formulation and potency (Levin, Oxman et al, unpublished), a large double blind, placebo controlled clinical trial ("The Shingles Prevention Study") was carried out in older adults to test the ability of zoster vaccine to decrease the Burden of Illness due to HZ and reduce the Incidence of PHN. 16 The Shingles Prevention Study (SPS) was a VA Cooperative Study carried out in collaboration with the National Institute of Allergy and Infectious Diseases and Merck & Co., Inc., with the approval of a Human Rights Committee of the VA Cooperative Studies Program and Institutional Review Boards at each of 22 study sites across the United States; each subject provided written Vaccination to Prevent Herpes Zoster and Postherpetic Neuralgia informed consent.…”

mentioning

confidence: 99%

Vaccination to Prevent Herpes Zoster and Postherpetic Neuralgia

Oxman¹

2007

Human Vaccines

View full text Add to dashboard Cite

Booster vaccination of healthy adults with VZV antibody but without a VZV-specific cell-mediated immune response

Cited by 12 publications

References 2 publications

Use of varicella vaccines to prevent herpes zoster in older individuals

Use of varicella vaccines to prevent herpes zoster in older individuals

Zoster Vaccine Live

Vaccination to Prevent Herpes Zoster and Postherpetic Neuralgia

Contact Info

Product

Resources

About